UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

British journal of cancer, 2012-04, Vol.106 (8), p.1367-1373

2012

Volltextzugriff (PDF)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

British journal of cancer, 2014-08, Vol.111 (4), p.689-695

2014

Volltextzugriff (PDF)

Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe

Annals of oncology, 2018-10, Vol.29, p.viii752-viii752

2018

Volltextzugriff (PDF)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

British journal of cancer, 2014-03, Vol.110 (5), p.1139-1147

2014

Volltextzugriff (PDF)

Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs

Annals of oncology, 2018-10, Vol.29, p.viii564-viii565

2018

Volltextzugriff (PDF)

Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)

Annals of oncology, 2018-10, Vol.29, p.viii564-viii564

2018

Volltextzugriff (PDF)

Electronic health records and patient registries in medical oncology departments in Spain

Clinical & translational oncology, 2021-10, Vol.23 (10), p.2099-2108

2021

Volltextzugriff (PDF)

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

European journal of cancer (1990), 2015-09, Vol.51, p.S183-S183

2015

Volltextzugriff (PDF)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2017-09, Vol.18 (9), p.1274-1284

2017

Volltextzugriff (PDF)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2021-05, Vol.22 (5), p.620-631

2021

Volltextzugriff (PDF)

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S176-S177

2015

Volltextzugriff (PDF)

266 Predictive and prognostic value of microtubule-associated protein-tau and classes I to IV b-tubulin isotypes in locally advancedbreast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S48-S48

2015

Volltextzugriff (PDF)

1703P Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022

Annals of oncology, 2023-10, Vol.34, p.S930-S930

2023

Volltextzugriff (PDF)

1706P Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway

Annals of oncology, 2023-10, Vol.34, p.S931-S931

2023

Volltextzugriff (PDF)

Clinical benefit and prices of cancer drugs in the US and Europe

Annals of oncology, 2019-10, Vol.30, p.v924

2019

Volltextzugriff (PDF)

1631PD_PR - Clinical benefit and prices of cancer drugs in the US and Europe

Annals of oncology, 2019-10, Vol.30, p.v924-v924

2019

Volltextzugriff (PDF)

1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time

Annals of oncology, 2023-10, Vol.34, p.S931-S931

2023

Volltextzugriff (PDF)

1938P Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)

Annals of oncology, 2023-10, Vol.34, p.S1041-S1041

2023

Volltextzugriff (PDF)

1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies

Annals of oncology, 2020-09, Vol.31, p.S961-S962

2020

Volltextzugriff (PDF)

1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade

Annals of oncology, 2020-09, Vol.31, p.S961-S961

2020

Volltextzugriff (PDF)

1631PD_PRClinical benefit and prices of cancer drugs in the US and Europe

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

Annals of oncology, 2019-10, Vol.30, p.v671

2019

Volltextzugriff (PDF)

1627OChange in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

Annals of oncology, 2019-10, Vol.30, p.v671-v671

2019

Volltextzugriff (PDF)

1552P Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST

Annals of oncology, 2021-09, Vol.32, p.S1127-S1127

2021

Volltextzugriff (PDF)

1 – 25 von 330

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(266)
Mit Volltextzugriff
(270)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Life Sciences & Biomedicine
(112)
Humans
(57)
Female
(40)
Oncology
(34)
Animals
(32)
Swine
(28)
Agriculture
(27)
Agriculture, Dairy & Animal Science
(26)
Technology
(24)
Male
(23)
Biological And Medical Sciences
(20)
Hogs
(20)
Computer Science
(19)
Aged
(18)
Middle Aged
(16)
Antineoplastic Agents - Therapeutic Use
(14)
Cancer Therapies
(14)
Fatty Acids
(14)
Adult
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(26)
Journal Of Clinical Oncology
(24)
Cancer Research
(15)
Journal Of Animal Science
(12)
Livestock Science
(8)
Revista Española De Derecho Canónico
(8)
Atherosclerosis
(6)
Plos One
(6)
Revista De Neurologiá
(6)
Jama Oncology
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs

Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)

Electronic health records and patient registries in medical oncology departments in Spain

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

266 Predictive and prognostic value of microtubule-associated protein-tau and classes I to IV b-tubulin isotypes in locally advancedbreast cancer

1703P Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022

1706P Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway

Clinical benefit and prices of cancer drugs in the US and Europe

1631PD_PR - Clinical benefit and prices of cancer drugs in the US and Europe

1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time

1938P Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)

1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies

1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade

1631PD_PRClinical benefit and prices of cancer drugs in the US and Europe

Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

1627OChange in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

1552P Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST

Suchergebnisse filtern